nLs-BG129

nLs-BG129 is a first-in-class targeted nanoliposomal peptide formulation designed for the treatment of advanced malignancies, specifically pancreatic ductal adenocarcinoma (PDAC). The drug consists of a synthetic peptide, BG129, which acts as a potent antagonist of the gastrin-releasing peptide receptor (GRPR). GRPR is a G protein-coupled receptor that is significantly overexpressed in various cancers, including pancreatic, prostate, and lung cancers, where it drives tumor cell proliferation, survival, and metastasis. By encapsulating the BG129 peptide within a nanoliposome, the formulation enhances the peptide's stability, protects it from proteolytic degradation, and extends its circulatory half-life. This delivery system also facilitates improved accumulation of the therapeutic peptide at the tumor site through the enhanced permeability and retention (EPR) effect. Developed by Nanolipo, nLs-BG129 has demonstrated significant anti-tumor activity in preclinical models and is currently undergoing evaluation in Phase 1 clinical trials to determine its safety, tolerability, and preliminary efficacy in patients with advanced pancreatic cancer.

Other names

nanoliposomal BG129